Bitifrin 0.3 mg/ml + 5 mg/ml eye drops, solution Ireland - English - HPRA (Health Products Regulatory Authority)

bitifrin 0.3 mg/ml + 5 mg/ml eye drops, solution

farmaprojects s.a. - bimatoprost; timolol maleate - eye drops, solution - timolol, combinations

Sturiban Eye Drops Solution 0.1mg/ml Malta - English - Medicines Authority

sturiban eye drops solution 0.1mg/ml

actavis group ptc ehf - bimatoprost - eye drops, solution - bimatoprost 0.1 mg/ml - ophthalmologicals

Sturiban Eye Drops Solution 0.3mg/ml Malta - English - Medicines Authority

sturiban eye drops solution 0.3mg/ml

actavis group ptc ehf - bimatoprost - eye drops, solution - bimatoprost 0.3 mg/ml - ophthalmologicals

Bimatoprost Actavis New Zealand - English - Medsafe (Medicines Safety Authority)

bimatoprost actavis

teva pharma (new zealand) limited - bimatoprost 0.1 mg/ml;   - eye drops, solution - 0.1 mg/ml - active: bimatoprost 0.1 mg/ml   excipient: benzalkonium chloride citric acid monohydrate dibasic sodium phosphate heptahydrate hydrochloric acid sodium chloride sodium hydroxide water for injection - bimatoprost actavis is indicated as monotherapy for the reduction of elevated intraocular pressure (iop) in patients with chronic glaucoma or ocular hypertension; or as adjunctive therapy in patients not adequately controlled on other agents.

Bimatoprost Actavis New Zealand - English - Medsafe (Medicines Safety Authority)

bimatoprost actavis

teva pharma (new zealand) limited - bimatoprost 0.3 mg/ml;   - eye drops, solution - 0.3 mg/ml - active: bimatoprost 0.3 mg/ml   excipient: benzalkonium chloride citric acid monohydrate dibasic sodium phosphate heptahydrate hydrochloric acid sodium chloride sodium hydroxide water for injection - bimatoprost actavis is indicated as monotherapy for the reduction of elevated intraocular pressure (iop) in patients with chronic glaucoma or ocular hypertension; or as adjunctive therapy in patients not adequately controlled on other agents.

GANFORT PF 0.3/5  bimatoprost 0.3 mg/mL and timolol (as maleate) 5.0 mg/mL eye drops Australia - English - Department of Health (Therapeutic Goods Administration)

ganfort pf 0.3/5 bimatoprost 0.3 mg/ml and timolol (as maleate) 5.0 mg/ml eye drops

abbvie pty ltd - timolol maleate, quantity: 6.8 mg/ml (equivalent: timolol, qty 5 mg/ml); bimatoprost, quantity: 300 microgram/ml - eye drops, solution - excipient ingredients: dibasic sodium phosphate heptahydrate; hydrochloric acid; citric acid monohydrate; purified water; sodium chloride; sodium hydroxide - ganfort pf 0.3/5 eye drops are indicated for the reduction of intraocular pressure (iop) in patients with chronic open-angle glaucoma or ocular hypertension who are insufficiently responsive to monotherapy.

GANFORT 0.3/5 bimatoprost 0.3 mg/mL & timolol (as maleate) 5.0 mg/mL eye drops bottle Australia - English - Department of Health (Therapeutic Goods Administration)

ganfort 0.3/5 bimatoprost 0.3 mg/ml & timolol (as maleate) 5.0 mg/ml eye drops bottle

abbvie pty ltd - timolol maleate, quantity: 6.8 mg/ml (equivalent: timolol, qty 5 mg/ml); bimatoprost, quantity: 0.3 mg/ml - eye drops, solution - excipient ingredients: dibasic sodium phosphate heptahydrate; benzalkonium chloride; sodium hydroxide; purified water; citric acid monohydrate; hydrochloric acid; sodium chloride - ganfort eye drops are indicated for the reduction of intraocular pressure (iop) in patients with chronic open-angle glaucoma or ocular hypertension who are insufficiently responsive to monotherapy.

LUMIGAN bimatoprost 300 micrograms/mL eye drops bottle Australia - English - Department of Health (Therapeutic Goods Administration)

lumigan bimatoprost 300 micrograms/ml eye drops bottle

abbvie pty ltd - bimatoprost, quantity: 300 microgram/ml - eye drops, solution - excipient ingredients: hydrochloric acid; benzalkonium chloride; sodium hydroxide; purified water; citric acid monohydrate; dibasic sodium phosphate heptahydrate; sodium chloride - for the reduction of elevated intraocular pressure, or open angle glaucoma, as first line therapy or monotherapy or as adjunctive therapy to topical beta-blockers.